Yunnan Yuxi Weihe Pharmaceutical

Yunnan Yuxi Weihe Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the modernization and production of Traditional Chinese Medicine (TCM), with a core focus on Panax notoginseng (Sanqi) derivatives. Established in 1992 and based in Yuxi, Yunnan, the company has developed a comprehensive industrial chain that includes herbal cultivation, advanced extraction, and large-scale manufacturing. Its flagship Xuesaitong series, which utilizes Panax notoginseng saponins, is a market leader in China for treating cardiovascular and cerebrovascular conditions such as ischemic stroke and coronary heart disease. The company operates multiple GMP-certified production lines and is recognized as a key high-tech enterprise within the Yunnan pharmaceutical cluster. Beyond its core pharmaceutical business, Weihe also produces health supplements and natural personal care products.